PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
18487651-5	2008	Analysis within the CD8alpha(+) population of T cells revealed that DEX treatment also reduced the CD8alpha(low) subset of gammadeltaT cells coexpressing the activation marker ACT-2(+).	Dexamethasone	68-71	CD8a molecule	Bos taurus	20-28	
18487651-5	2008	Analysis within the CD8alpha(+) population of T cells revealed that DEX treatment also reduced the CD8alpha(low) subset of gammadeltaT cells coexpressing the activation marker ACT-2(+).	Dexamethasone	68-71	CD8a molecule	Bos taurus	99-107	
18487651-7	2008	Dexamethasone treatment reduced the number of gammadeltaT cells but increased the percentages of CD14(+) monocytes and activated CD25(+) cells (both CD4(-) and CD4(+)) in peripheral blood mononuclear cell (PBMC) preparations.	Dexamethasone	0-13	CD14 molecule	Bos taurus	97-101	
18487651-7	2008	Dexamethasone treatment reduced the number of gammadeltaT cells but increased the percentages of CD14(+) monocytes and activated CD25(+) cells (both CD4(-) and CD4(+)) in peripheral blood mononuclear cell (PBMC) preparations.	Dexamethasone	0-13	interleukin 2 receptor subunit alpha	Bos taurus	129-133	
18487651-7	2008	Dexamethasone treatment reduced the number of gammadeltaT cells but increased the percentages of CD14(+) monocytes and activated CD25(+) cells (both CD4(-) and CD4(+)) in peripheral blood mononuclear cell (PBMC) preparations.	Dexamethasone	0-13	CD4 molecule	Bos taurus	149-152	
18487651-7	2008	Dexamethasone treatment reduced the number of gammadeltaT cells but increased the percentages of CD14(+) monocytes and activated CD25(+) cells (both CD4(-) and CD4(+)) in peripheral blood mononuclear cell (PBMC) preparations.	Dexamethasone	0-13	CD4 molecule	Bos taurus	160-163	
18487651-8	2008	Although DEX treatment reduced the overall proliferative capacity of PBMC, it enhanced the relative number of proliferating CD4(+) lymphocytes.	Dexamethasone	9-12	CD4 molecule	Bos taurus	124-127	
18487651-9	2008	Lower levels of mRNA for several Th-prototype cytokines (IL-2, IFN-beta, IL-4, transforming growth factor-beta) were detected in short-term PBMC cultures established from DEX-treated calves compared with PBMC cultures from control calves; the amount of il-10 transcripts, however, was unaffected.	Dexamethasone	171-174	interleukin 2	Bos taurus	57-61	
18487651-9	2008	Lower levels of mRNA for several Th-prototype cytokines (IL-2, IFN-beta, IL-4, transforming growth factor-beta) were detected in short-term PBMC cultures established from DEX-treated calves compared with PBMC cultures from control calves; the amount of il-10 transcripts, however, was unaffected.	Dexamethasone	171-174	interferon beta-1	Bos taurus	63-71	
18487651-9	2008	Lower levels of mRNA for several Th-prototype cytokines (IL-2, IFN-beta, IL-4, transforming growth factor-beta) were detected in short-term PBMC cultures established from DEX-treated calves compared with PBMC cultures from control calves; the amount of il-10 transcripts, however, was unaffected.	Dexamethasone	171-174	interleukin 4	Bos taurus	73-77